Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03658109
Other study ID # 56789013
Secondary ID
Status Terminated
Phase Early Phase 1
First received
Last updated
Start date September 24, 2019
Est. completion date May 4, 2021

Study information

Verified date May 2021
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study may provide evidence for whether or not systemic lidocaine infusion offers significant advantage over truncal regional blocks in gynecology oncology surgery patients in terms of post-operative analgesia, recovery, and safety profile. Further, it may show whether there is any increased efficacy of adding truncal regional block or systemic lidocaine versus intrathecal opioid administration alone.


Description:

Systemic administration of intravenous lidocaine has a number of observed and theoretical advantages in the perioperative period. Systematic review of perioperative lidocaine infusions has shown a reduction in early post-operative pain scores in patients undergoing abdominal surgery, positive effects for GI recovery, reduction in post-operative opioid requirements, reduction in the incidence of post-operative nausea and vomiting, and decreased length of hospital stay. They have been shown to modulate the surgery-induced stress response in colorectal surgery and abdominal hysterectomy. Thoracic epidural analgesia was better as compared to intravenous lidocaine in a RCT of patients undergoing laparoscopic colorectal surgery as part of an enhanced recovery program, though there was similar impact on recovery of bowel function. Truncal regional anesthesia has been utilized in open and closed abdominal operations with various levels of efficacy. A statistically significant, though marginal clinical analgesic benefit, by recorded opioid consumption, has been concluded by meta-analysis in patients undergoing abdominal laparotomy, laparoscopy, or cesarean delivery after US-guided TAP block. There was not found to be any additional benefit of TAP block in patients who received a spinal anesthetic that included a long-acting opioid. The interpretation of results was noted to be limited by the heterogeneity of the included studies and analysis, though. The conclusions of one study of open prostatectomy, as part of an ERP, was that neither systemic lidocaine nor TAP block improved post-operative analgesia. Both IV lidocaine and TAP block groups showed a reduction in post-operative opioid consumption, though to an insignificant degree. It was noted as a possibility that the other interventions as part of the ERP, such as scheduled administration of IV acetaminophen, could have resulted in the non-significant decrease in post-operative opioid requirement. A recent review of the use of TAP blocks in major gynecological, non-obstetric, surgery, including total abdominal hysterectomy, concluded that TAP blocks may contribute to early post-operative analgesia, with marginal additional benefit if multimodal analgesic regimens including NSAIDs and acetaminophen are added. It was hypothesized by the authors that some of the limited benefit might be due to the fact that US-guided TAP blocks are primarily useful for somatic pain, but that major gynecologic surgery has a large visceral pain component. There are limited randomized studies involving Quadratus Lumborum block (QL) at this time. QL block has shown improved analgesia in abdominal operations as compared to TAP block and is thought to have potentially greater relief of visceral pain. There is a case report of motor weakness following anterior, lateral QL block for gynecologic laparoscopy, thought to be related to spread of the block to affect the L2 dermatome on one side. It has not been determined if this is a common occurrence or may be affected by the type of QL block performed. Prior to this study, truncal regional anesthesia was used in the UAB Gynecology-Oncology Surgery Enhanced Recovery Program as an analgesic alternative for those who were not good candidates for intrathecal opioid injection. A comparison of QL block versus systemic lidocaine infusion or whether either of these interventions has utility over intrathecal opioid administration alone has yet to be described.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date May 4, 2021
Est. primary completion date May 4, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 69 Years
Eligibility Inclusion Criteria: - Adult patients undergoing gynecologic-oncology surgery involving a mid-line laparotomy incision and as part of the local ERP, who are initially identified as an outpatient - 18 years of age or older Exclusion Criteria: - Pregnancy, - BMI>45, - Age >70, - Actual weight <65 kg - Severe COPD - Severe asthma - Other severe respiratory disease (ILD, etc.) - Local anesthetic allergy - History of cardiac arrhythmia or heart block - CHF - Use of oral anti-arrhythmia agents or lidocaine analogues (i.e. mexiletine) - Inability to be a candidate for intrathecal opioid injection based on medical history and provider judgement

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lidocaine Bolus Infusion
Patients will undergo Lidocaine Bolus infusion.
Procedure:
QL block
Patients will undergo a posterior QL block pre-operatively
Drug:
Saline Bolus Infusion
Patients will undergo Saline Bolus infusion.
Procedure:
Simulated QL block
Patients will undergo a simulated posterior QL block pre-operatively.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary PACU Post-operative opioid consumption Total opioid consumption (measured in oral morphine equivalents) From 0 to 12 hours post surgery
Secondary Length of PACU admittance to time of readiness for discharge from PACU This outcome measure will reflect the total amount of time required for the patient to be deemed suitable for discharge from the PACU, starting from the time of admittance to the PACU. Time of PACU admittance to the time of PACU readiness for discharge, generally not more than 12 hours
Secondary PACU Sedation Scores This score will be collected using the modified Aldrete scale, every 15 minutes for the first hour of PACU stay, and once per hour for any additional hour(s) of PACU stay using a method consisting of: Consciousness = fully awake (2 points), arousable (1 point), not responding (0 points). This scale is used to determine a participant's state of arousal. The range of the scale is from 0-2, with zero being the most unresponsive and two being the most responsive. From 0 to 12 hours post surgery
Secondary Length of hospital stay Time of admission until time of discharge, generally not over 1 week
Secondary Ambulation on POD 0 and POD1 Number of minutes spent ambulating, per subject and/or nurse reporting From 0 to 96 hours post surgery
Secondary Return to bowel function Return to bowel function (return of flatus, BM, ability to tolerate PO), per subject and/or nurse reporting From 0 to 96 hours post surgery
Secondary Total Opioid Dose Utilized During Surgery likely expressed as mcg of fentanyl but may be converted to morphine equivalent dose if multiple opioids are used From one hour before surgery start time to one hour after procedure stop time
Secondary Presence or Absence of Patient Controlled Analgesia Whether or not a PCA is needed for post-operative analgesia (Y/N - per usual documentation in the EMR. From 0 to 96 hours post surgery
Secondary Time to First Opioid Use time from admission to the floor to administration of first opioid medication (per usual nursing documentation in the EMR). From 0 to 96 hours post surgery
Secondary Average PACU Pain Score This outcome will be measured by taking the average of the numerical pain scale used to assess a patient's pain levels throughout their time in the PACU. The numerical pain scale has a range of 0 to 10, with 0 being no pain and 10 being very severe pain. From 0 to 12 hours post surgery
Secondary Post Operative Pain Scores This outcome will be measured by taking the value of the numerical pain scale used to assess a patient's pain levels throughout their time in the hospital that is closest to each 4 hours after the time of the anesthesia documentation finish From 0 to 72 hours post surgery
Secondary Average PACU opioid consumption Average total amount of opioids consumed in the PACU From 0 to 12 hours post surgery
Secondary Post-operative opioid consumption Post-operative opioid consumption (measured in oral morphine equivalents) From 0 to 72 hours post surgery
See also
  Status Clinical Trial Phase
Completed NCT04890327 - Web-based Family History Tool N/A
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Recruiting NCT05478876 - Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract N/A
Active, not recruiting NCT04899492 - Evaluation of Different Smoking Cessation Protocols: Nicotine Replacement, Motivational Interviewing (MI), Cognitive Behavioural Therapy (CBT) or Hypnotherapy in Cancer Patients Scheduled for Surgery N/A
Recruiting NCT05296512 - Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer Phase 2
Not yet recruiting NCT06398314 - Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors N/A
Completed NCT01679483 - Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer N/A
Completed NCT01444924 - Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery Phase 2
Recruiting NCT05053230 - A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer N/A
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Active, not recruiting NCT04584957 - Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.) N/A
Completed NCT03292328 - Yoga for Symptoms of Nerve Damage Caused by Chemotherapy N/A
Completed NCT02459301 - A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies Phase 1
Completed NCT05131490 - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients N/A
Active, not recruiting NCT03899376 - A Trial Comparing Acute Toxicity in Patients With Gynecological Cancer Treated With VMAT N/A
Not yet recruiting NCT05407987 - Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) Phase 3
Recruiting NCT05891470 - To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT N/A
Not yet recruiting NCT05974995 - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer N/A
Withdrawn NCT04368130 - SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care N/A
Recruiting NCT04806724 - Opening the Conversation Study N/A